Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Iranian enoxaparin with Clexane in hospitalized patients
IRCT20230809059099N1Phase 4Completed
- Sponsor
- Alborz Darou
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of enoxaparin in acute coronary syndrome (ACS) and venous thromboembolism (VTE) (2 arms), sponsored by Alborz Darou. Primary endpoint: Anti-factor Xa activity. Started Oct 2023; status: completed.
02
Drugs
enoxaparin
03
Conditions
acute coronary syndrome (ACS)venous thromboembolism (VTE)
Beyond the preview
Go deeper on IRCT20230809059099N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230809059099N1.